Pharmacokinetics of intravenous bepridil in patients with coronary disease

The pharmacokinetics of intravenous bepridil (1-[2-(N-benzylanilino)-1-(isobutoxymethyl)ethyl]pyrrolidine ) were studied in 16 patients undergoing cardiac catheterization for evaluation of coronary disease, all with normal base-line hemodynamic and renal functions. Ten patients received 3 mg/kg and six patients received 4 mg/kg of bepridil infused over a period of 30 min. Plasma bepridil concentrations were measured by HPLC and analyzed by model-dependent and model-independent methods. The mean (+/- SD) maximum plasma bepridil concentrations at the end of the infusion were 2047 +/- 820 ng/mL (3 mg/kg) and 2478 +/- 1426 ng/mL (4 mg/kg). Postinfusion bepridil concentrations were best described by a two-compartment open model. The model-dependent harmonic mean distribution and elimination half-lives were 1.7 h (range: 1.1-2.2 h) and 19.7 h (range: 8.0-61.9 h), respectively. The harmonic mean elimination half-life from model-independent analysis was 14.9 h (range: 7.4-64.0 h). The arithmetic means of other model-independent kinetic parameters were systemic clearance, 0.524 +/- 0.215 L X kg-1 X h-1; Vd, 15.3 +/- 10.9 L/kg; and Vdss, 10.1 +/- 6.0 L/kg. Model-dependent and model-independent estimates of half-life and clearance agreed reasonably well. Bepridil was well tolerated, effecting little or no change in central hemodynamics or EKG intervals. The extensive distribution and relatively slow clearance of bepridil account for its long elimination half-life. Intravenous bepridil appears to be a safe calcium (II) antagonist that is suitable for once-a-day dosing.     

Depression in patients with cancer

This paper reviews the clinical aspects of depression in cancer from the perspective of prevalence, diagnosis, clinical symptoms, classification and treatment. Clinical trials, reported since 1960, of psychosocial, psychopharmacologic and behavioral interventions are critically evaluated. Therapeutic guidelines are offered for the management of the depressed patients with cancer. Research directions are suggested for the future.     

Quantitative immunofluorescence assay for cyclobutyldithymidine dimers in individual mammalian cells

An indirect immunofluorescence procedure was developed for themeasurement of cyclobutyl dithymidine dimers in DNA of individualSyrian hamster embryo cells using a specific monoclonal antibody.A fluorescein-labeled secondary antibody and a fluorochromewhich binds to DNA were used to measure the photoproduct andtotal DNA in the same nucleus. Fluorescence intensity was quantitatedwith a computer-assisted microfluorometric system which wascalibrated with a uranyl oxide impregnated glass slide. Similardose-response curves, i.e. normalized fluorescence intensityplotted as a function of dose of germicidal irradiation, wereobtained with two different cell types. Normalized fluorescenceintensity per nucleus was related to thymidine dimer contentwith a competitive enzyme-linked imnmunosorbent assay usingDNA isolated from cells given doses of germicidal irradiationidentical to those used in the immunofluorescence assay. Thymidinedimer levels produced by 10 J/m² of germicidal irradiation (8x10⁵/nucleus)and which allow for 15–30% cell survival can readily bedetected. The specific monoclonal antibody was labeled withtritium and used in the immunofluorescence assay to relate thenumber of antibodies bound to the number of thynudine dimersper cell. The data revealed that 45% of the thymidine dimersin cells exposed to 100 J/m² of germicidal irradiation and essentiallyall the T<>T in cells receiving 20 J/m² were being detectedin the indirect immunofluorescence assay. This technique canprovide a sensitive means for measuring various types of DNAdamage in individual cells given that the appropriate probesare available. It can be especially useful for monitoring occupationallyor environmentally exposed populations where usually only smallsamples of cells or tissues are available.     

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

Recent advances in in vitro metabolism methods have led to an improved ability to predict clinically relevant metabolic drug-drug interactions. To address the relationships of in vitro metabolism data and in vivo metabolism outcomes, the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research, Food and Drug Administration, evaluated a number of recently approved new drug applications. The goal of these evaluations was to determine the contribution of in vitro metabolism data in (1) predicting in vivo drug-drug interactions, (2) determining the need to conduct an in vivo drug-drug interaction study, and (3) incorporating findings into drug product labeling. Ten cases are presented in this article. They fall into two major groups: (1) in vitro data were predictive of in vivo results, and (2) in vitro data were not predictive of in vivo results. Discussion of these cases highlights factors limiting predictability of in vivo metabolic interactions from in vitro metabolism data. The integration of these findings into drug product labeling is also discussed.     

Psychological distress in parents consenting to child's bone marrow transplantation

The purpose of this study was to determine the nature and prevalence of the psychological symptomatology in parents of children undergoing bone marrow transplantation (BMT) and to investigate the manner in which certain psychosocial factors are related to parental distress associated with the informed consent process. A total of 61 parents (46 mothers and 15 fathers) were assessed with respect to psychological distress, coping styles, quality of physician-patient communication, and recall of BMT information after providing written consent for their child to have BMT. Forty-seven percent of fathers and 60% of mothers exhibited significant psychological distress of a generalized nature. Mothers exhibited a broader range of specific psychological symptomatology and more severe levels of depression and phobic anxiety than did fathers. The level of parents' distress was unrelated to characteristics of their child's disease or treatment milieu, or to parents' recall of BMT information. However, emotional coping was positively related to psychological distress whereas the quality of the communication between physician and parent was inversely related. The findings from this study suggest that approximately 50% of all parents could benefit from psychological interventions which promote the efficient utilization of coping strategies and highlight the importance of the nature of the communication style used by oncologist-investigators in obtaining informed consent.     

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

Using pharmacogenetics-based therapy, clinicians can estimate the therapeutic warfarin dose by genotyping patients for single nucleotide polymorphisms (SNPs) that affect warfarin metabolism or sensitivity. SNPs in the cytochrome P450 complex (CYP2C9) affect warfarin metabolism: patients who have the CYP2C9*2 and/or CYP2C9*3 variants metabolize warfarin slowly and are more likely to have an elevated International Normalized Ratio INR or to hemorrhage during warfarin initiation than patients without these variants. SNPs in vitamin K epoxide reductase (VKORC1) correlate with warfarin sensitivity. Patients who are homozygous for a common VKORC1 promoter polymorphism, −1639 G>A (also designated as VKOR 3673, haplotype A, or haplotype*2), are warfarin sensitive and typically require lower warfarin doses. By providing an estimate of the therapeutic warfarin dose, pharmacogenetics-based therapy may improve the safety of anticoagulant therapy. To improve drug safety, the FDA updates labels of previously approved drugs as new clinical and genetic evidence accrues. The labels of medical products serve to inform prescribers and patients about potential ways to improve the benefit/risk ratio and/or optimize doses of medical products. On August 16, 2007, the FDA updated the label of warfarin to include information on pharmacogenetic testing and to encourage, but not require, the use of this information in dosing individual patients initiating warfarin therapy. The FDA completed the label update in August 2007. Disclosure: A portion of this article was adapted from an education handout that Dr. Gage has retained copyright of: Gage, B.F. (2006). Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program: 467–473. Dr. Gage has served as a consultant to Bristol-Myers Squibb. Funding: NIH R01 HL074724.     

Associations of Drug Use,Violence, and Depressive Symptoms with Sexual Risk Behaviors Among Women with Alcohol Misuse

Background

Alcohol misuse is associated with increased human immunodeficiency virus sexual risk behaviors by women. Drug use, intimate partner violence (IPV), and depressive symptoms frequently co-occur, are well-recognized alcohol misuse comorbidities, and may interact to increase risk behaviors. Using a syndemic framework we examined associations between drug use, IPV, and depressive symptoms and sexual risk behaviors by 400 women with alcohol misuse attending an urban sexually transmitted infections clinic.